NASDAQ:APVO Aptevo Therapeutics (APVO) Stock Price, News & Analysis $4.86 +0.31 (+6.81%) As of 02:48 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Aptevo Therapeutics Stock (NASDAQ:APVO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aptevo Therapeutics alerts:Sign Up Key Stats Today's Range$4.59▼$4.8550-Day Range$3.96▼$5.6152-Week Range$3.80▼$235.98Volume6,412 shsAverage Volume122,258 shsMarket Capitalization$6.08 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview Aptevo Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system. The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life. Key product candidates in Aptevo’s pipeline include AFM13, a CD30/CD16A innate cell engager in development for CD30-positive lymphomas, and APVO436, a bispecific molecule targeting CD123 and CD3 for acute myeloid leukemia. Aptevo Therapeutics conducts clinical studies across North America and Europe, partnering with academic centers and industry collaborators to advance its lead candidates through Phase 1/2 trials. The company’s approach emphasizes dual activation of innate and adaptive immune responses to achieve potent antitumor effects while reducing the risk of off-target toxicity. Guided by a management team with extensive experience in biologic drug development and cell-based therapies, Aptevo continues to expand its pipeline and seek strategic partnerships to bring its immunotherapeutic candidates to patients with high-unmet medical needs.AI Generated. May Contain Errors. Read More Aptevo Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks24th Percentile Overall ScoreAPVO MarketRank™: Aptevo Therapeutics scored higher than 24% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.4 / 5Analyst RatingHold Consensus RatingAptevo Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 strong buy rating, no buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageAptevo Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Aptevo Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Aptevo Therapeutics are expected to grow in the coming year, from ($24.13) to ($21.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aptevo Therapeutics is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aptevo Therapeutics is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAptevo Therapeutics has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.81% of the float of Aptevo Therapeutics has been sold short.Short Interest Ratio / Days to CoverAptevo Therapeutics has a short interest ratio ("days to cover") of 5.09.Change versus previous monthShort interest in Aptevo Therapeutics has recently decreased by 11.55%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAptevo Therapeutics does not currently pay a dividend.Dividend GrowthAptevo Therapeutics does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.33 News SentimentAptevo Therapeutics has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Aptevo Therapeutics this week, compared to 2 articles on an average week.MarketBeat Follows4 people have added Aptevo Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aptevo Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders0.08% of the stock of Aptevo Therapeutics is held by insiders.Percentage Held by Institutions8.06% of the stock of Aptevo Therapeutics is held by institutions.Read more about Aptevo Therapeutics' insider trading history. Receive APVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aptevo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. APVO Stock News HeadlinesAptevo Therapeutics (NASDAQ:APVO) Stock Passes Below 50-Day Moving Average - What's Next?May 21 at 4:19 AM | americanbankingnews.comAptevo Therapeutics (NASDAQ:APVO) & Absci (NASDAQ:ABSI) Financial SurveyMay 16, 2026 | americanbankingnews.comSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.May 21 at 1:00 AM | Brownstone Research (Ad)Aptevo Therapeutics Inc APVOMay 6, 2026 | morningstar.comMAptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 ...May 6, 2026 | theglobeandmail.comAptevo Therapeutics (APVO) price target decreased by 99.72% to 21.42March 28, 2026 | msn.comAptevo Therapeutics: Aptevo Provides State of the Business Report and 2025 Financial ResultsMarch 26, 2026 | finanznachrichten.deAptevo Therapeutics: Aptevo to Participate in March 2026 ConferencesMarch 19, 2026 | finanznachrichten.deSee More Headlines APVO Stock Analysis - Frequently Asked Questions How have APVO shares performed this year? Aptevo Therapeutics' stock was trading at $9.43 at the beginning of 2026. Since then, APVO stock has decreased by 50.5% and is now trading at $4.67. How were Aptevo Therapeutics' earnings last quarter? Aptevo Therapeutics Inc. (NASDAQ:APVO) posted its earnings results on Wednesday, May, 13th. The biotechnology company reported ($6.41) EPS for the quarter, hitting the consensus estimate of ($6.41). When did Aptevo Therapeutics' stock split? Aptevo Therapeutics shares reverse split on the morning of Wednesday, March 6th 2024.The 1-44 reverse split was announced on Wednesday, March 6th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, March 6th 2024. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of Aptevo Therapeutics? Shares of APVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aptevo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aptevo Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Alibaba Group (BABA), Plug Power (PLUG) and Micron Technology (MU). Company Calendar Last Earnings5/13/2026Today5/21/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (59m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 APVO's financial health is in the Red zone, according to TradeSmith. APVO has been in this zone for over 59 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:APVO CIK1671584 Webwww.aptevotherapeutics.com Phone(206) 838-0500Fax206-838-0503Employees50Year Founded2016Profitability EPS (Trailing Twelve Months)($197.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$25.97 million Net MarginsN/A Pretax MarginN/A Return on Equity-198.50% Return on Assets-117.06% Debt Debt-to-Equity RatioN/A Current Ratio3.36 Quick Ratio3.36 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$9.32 per share Price / Book0.52Miscellaneous Outstanding Shares1,250,000Free Float1,245,000Market Cap$6.08 million OptionableNot Optionable Beta1.64 Social Links 7 Stocks to Ride The A.I. MegaboomWe are about to experience the greatest A.I. boom in stock market history... Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s. That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom. Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day. And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly... Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy. Get This Free Report This page (NASDAQ:APVO) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptevo Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptevo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
